Bladder Cancer PIII Results in 2Q 2010 !! Bioniche
Seite 1 von 46 Neuester Beitrag: 25.04.21 03:05 | ||||
Eröffnet am: | 17.01.10 12:54 | von: Biotechmaste. | Anzahl Beiträge: | 2.126 |
Neuester Beitrag: | 25.04.21 03:05 | von: Ursularwlra | Leser gesamt: | 198.626 |
Forum: | Hot-Stocks | Leser heute: | 45 | |
Bewertet mit: | ||||
Seite: < | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... 46 > |
Sollten die PIII-Ergebnisse positiv sein ist eine Kursexplosion garantiert .
Wer also gerne etwas riskiert könnte mit der Aktie reichlich belohnt werden .
Bioniche Life Science (BNC.TO)
Market Cap : 53 Mio C$
Cash : 20 Mio C$
Kurs : 0,61 C$
Insider activity
http://canadianinsider.com/coReport/allTransactions.php?ticker=bnc
Urocidin (Bladder Cancer) PII-Ergebnisse
http://www.medicalnewstoday.com/articles/139517.php
1,50 $ TGT by Haywood
http://www.haywood.com/pdffiles/BNCJul142009.pdf
SECTOR OUTPERFORM; Target: $1.50 Risk: SPECULATIVE
Partnership Agreement Puts BNC Back on Track
ALPHA: We see significant upside to investors. BNC's share price
reflects a value for the Animal Health division only - that is at 5x
2009 EBITDA or $0.50/shr. We note the US$20M upfront from the Endo
agreement is worth ~$0.25/shr alone. We disagree with the market that
the Human Health division with Urocidin is currently worth zero to BNC
and investors.
Hier habt Ihr die Chance bei einer zweiten Dendreon(DNDN) dabei zu sein . Unter 1$ ist die Aktie geschenkt !
Bioniche Life Science (BNC.TO)
Market Cap: 81 Mio C$
Cash: 30 Mio C$
Price: 0,94 C$
Bioniche shares jump 34% on Endo taking up global rights
February 12, 2010 by biotuesday
http://biotuesday.ca/2010/02/12/...4-on-endo-taking-up-global-rights/
Upcoming Milestones
2009/2010 Conditional license for E. coli cattle vaccine in the U.S.
2009/2010 Achievement of pre-commercialization milestone payments for
UrocidinTM
2010 First U.S. sales of E. coli cattle vaccine
2010 Results of refractory Phase III NMI bladder cancer trial
2011 Belleville, ON vaccine manufacturing centre operational
Insider activity
http://canadianinsider.com/coReport/allTransactions.php?ticker=bnc
Urocidin (Bladder Cancer) PII Results
http://www.medicalnewstoday.com/articles/139517.php
1,50 $ TGT by Haywood
http://www.haywood.com/pdffiles/BNCJul142009.pdf
SECTOR OUTPERFORM; Target: $1.50 Risk: SPECULATIVE
Partnership Agreement Puts BNC Back on Track
ALPHA: We see significant upside to investors. BNC's share price
reflects a value for the Animal Health division only - that is at 5x
2009 EBITDA or
.50/shr. We note the US$20M upfront from the Endo
agreement is worth ~
.25/shr alone. We disagree with the market that
the Human Health division with Urocidin is currently worth zero to BNC and investors.
RALLLLYYYYYYYY
http://de.advfn.com/...art&s=TSE%3ABNC&p=0&t=37&vol=1
Crystal Research ... Schöne Analyse
http://www.crystalra.com/pdf/BNC_2QFY10_Update_02-18-10.pdf
Urocidin (Blasenkrebs) PIII results in 2Q 2010 .Urocidin hat BLOCKBUSTER POTENTIAL !!!!
Bioniche Life Science (BNC.TO)
Market Cap: 105 Mio C$
Cash: 30 Mio C$
Price: 1,21 C$
Upcoming Milestones
2009/2010 Conditional license for E. coli cattle vaccine in the U.S.
2009/2010 Achievement of pre-commercialization milestone payments for
UrocidinTM
2010 First U.S. sales of E. coli cattle vaccine
2010 Results of refractory Phase III bladder cancer trial
2011 Belleville, ON vaccine manufacturing centre operational
Insider activity
http://canadianinsider.com/coReport/allTransactions.php?ticker=bnc
Strong Bullish Chart
http://www.barchart.com/opinions/BNC.TO
Urocidin Potential New Treatment for Bladder Cancer
http://www.associatedcontent.com/article/1939454/...r_pg3.html?cat=70
Urocidin (Bladder Cancer) PII Results
http://www.medicalnewstoday.com/articles/139517.php
Discussion board of people dealing with bladder cancer and discussing BCG treatment and MCC
http://www.inspire.com/groups/...cussion/bcg-protocol/?page=1#replies
Crystal Research 18.02.2010
http://www.crystalra.com/pdf/BNC_2QFY10_Update_02-18-10.pdf
BNC könnte sich ähnlich entwickeln wie Dendreon .
Barchart
http://www.barchart.com/quotes/BNC.TO
Best-Rated Canadian Stocks Updated Apr 25, 2010
5 Bioniche Life Sciences (TSE:BNC) 1.00 Strong Buy
http://www.nasd100.com/2010/04/...ian-stocks-updated-apr-25-2010.html
Bioniche Life Science (BNC.TO)
Marktkap: 72 Mio $
Cash: 22 Mio $
Kurs: 0,97 $
Dundee Sec Juni 2010
Bioniche has three businesses with diversified risk/reward profiles: Animal Health, which is expected to generate around $28 million in sales in fiscal 2010; Human Health, with Phase 3 results expected in mid-2010 from lead product, Urocidin, testing for bladder cancer; and Food Safety, with Canadian approval and a conditional license pending in the U.S. of a vaccine for reducing E. coli 0157 in cattle feces, and a pipeline of other vaccines.
Mr. Martin points out that Urocidin provides the “biggest upside potential” for Bioniche investors. His initial diligence suggests that Urocidin has a “relatively high overall probability of approval,” even though the first of two planned Phase 3 trials has a moderate level of risk, as the refractory patients enrolled in the trial are a “tougher-to-treat” population than was enrolled in the Phase 2 trial, he says.
Mitigating the risk somewhat is the 20% “complete response” hurdle required for Phase 3. That compares with the company’s Phase 2 results, where patients achieved a 46.4% CR rate at 26 weeks in a population that was mainly relapsed but also included a few patients being treated for the first time.
A second planned Phase 3 trial will test Urocidin head-to-head against the current standard of care, baccilus Calmette-Guerin (BCG) in first-line treatment, “where we expect Urocidin to demonstrate better efficacy, based on prior data, and superior safety and tolerability,” he predicts.
In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to Endo Pharmaceuticals. Based on incidence of bladder cancer and possible pricing, he figures the global market opportunity for Urocidin in the refractory population could be $800 million. If the second Phase 3 trial expands the Urocidin label to first-line treatment, the market opportunity could grow to an estimated $2 billion.
“Twenty-five percent penetration of this market would represent $500 million in annual sales and an estimated $112.5 million in gross profit for Bioniche,” Mr. Martin says
Realtime Chart
http://ih.advfn.com/...l=TSE:BNC&period=0&size=19&volume=
Nur 105 Patienten befinden sich in der aktuellen PIII Programm deshalb sind die Chancen auf positive Daten sehr groß !!!!
In November 2008,
during a meeting of urologists in Santigo Chile, the biopharmaceutical research company presented positive clinical studies (one and two) involving 130 bladder cancer patients treated with Urocidin. Elderly patients (average 73 years old) during the clinical studies noted excellent safety results
Ein paar Zeichen die für gute Daten sprechen ....
UPDATE 1-Bioniche gets $6 mln milestone payment from Endo Pharma
http://www.reuters.com/article/idUSBNG43432420091106
---
Bioniche obtains two additional milestones under licensing agreement with Endo
http://www.tradingmarkets.com/news/stock-alert/...niche-obtains-two-a
dditional-milestones-under-licensing-agreement-with-endo-777521.html
--
Alle DMC (Data Monitoring Committee) meetings waren Positiv !!!!
Bioniche Phase III Clinical Trial With Urocidin(TM) Given Continued Green Light By DMC
http://www.medicalnewstoday.com/articles/161677.php
Upcoming Milestones 2010
2009/2010 Conditional license for E. coli cattle vaccine in the U.S. <<<<<< HUGE MILESTONE
2009/2010 Achievement of pre-commercialization milestone payments for
UrocidinTM
2010 First U.S. sales of E. coli cattle vaccine
2010 Results of refractory Phase III bladder cancer trial <<<<<<<<<HUGE MILESTONE
2011 Belleville, ON vaccine manufacturing centre operational
Die Phase3 Daten dürften bald da sein und falls positiv wovon ich ausgehe sehen wir hier locker kurse von 5$ und mehr .
Bioniche wird weiterhin mit Strong Buy bewertet .
http://www.freemarkettrends.com/2010/08/...or.html#uds-search-results
Top 100 Strong Buy Canadian stocks for August 1, 2010
Below are the top 100 Strong Buy Canadian stocks based on average Wall Street analyst ratings. Each analyst rating is assigned a number ranging from 1 to 5, with 1 being the highest rating (STRONG BUY) and 5 being the lowest rating (STRONG SELL). The average is calculated to represent the overall rating of a stock.
Ranking | Company | Average Rating Value | Average Rating
1 AlarmForce Industries (TSE:AF) 1.00 Strong Buy
2 Altius Minerals Corporation (TSE:ALS) 1.00 Strong Buy
3 Amorfix Life Sciences Ltd. (TSE:AMF) 1.00 Strong Buy
4 Aquila Resources Inc. (TSE:AQA) 1.00 Strong Buy
5 Aeroquest International Limited (TSE:AQL) 1.00 Strong Buy
6 Bioniche Life Sciences (TSE:BNC) 1.00 Strong Buy
Viel glück !
MFG
Chali
1. Die P3-Studie hat nur eine kleine Patientenanzahl (105) bei Antigenics waren es über 700 !!
2. Die Studie wurde zudem von der " Data Monitoring Committee" ( mehr dazu hier http://www.springerlink.com/content/768311514066n524/ ) überwacht und alle meetings sind positiv verlaufen .
3.Endo hat halbes jahr vor Ablauf der Frist die Option auf die Weltweiten Rechte ausgeübt ! Die Frage ist warum haben die das getan ???
Du siehst es gibt gründe um Optimistisch zu sein denoch kann man das Risiko nicht ausschließen .
Also ein super gutes Zeichen ...
http://finance.yahoo.com/news/...cal-cnw-2336203888.html?x=0&.v=1
Ich kann nur sagen Strong Buy für die interessiert sind .
Läuft alles gut dürfte 5$ bis ende 2010 kein problem sein .
Das erinnert mich an Neopharm (NEOL:PK) die hatten auch diese Catheder Geschichte,aber gegen Braintumor,der Wert jetzt in den Pinks,also gehe ich nicht davon aus,das es geklappt hat .....
Grummel